- Home
- GNRC vs ROIV Comparison
GNRC vs ROIV Comparison
Compare GNRC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- ROIV
- Stock Information
- Founded
- GNRC 1959
- ROIV 2014
- Country
- GNRC United States
- ROIV United Kingdom
- Employees
- GNRC N/A
- ROIV N/A
- Industry
- GNRC Metal Fabrications
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- GNRC Consumer Discretionary
- ROIV Health Care
- Exchange
- GNRC Nasdaq
- ROIV Nasdaq
- Market Cap
- GNRC 10.9B
- ROIV 8.4B
- IPO Year
- GNRC 2010
- ROIV N/A
- Fundamental
- Price
- GNRC $160.54
- ROIV $10.94
- Analyst Decision
- GNRC Buy
- ROIV Strong Buy
- Analyst Count
- GNRC 20
- ROIV 8
- Target Price
- GNRC $177.78
- ROIV $17.93
- AVG Volume (30 Days)
- GNRC 665.9K
- ROIV 5.3M
- Earning Date
- GNRC 02-12-2025
- ROIV 02-11-2025
- Dividend Yield
- GNRC N/A
- ROIV N/A
- EPS Growth
- GNRC 89.80
- ROIV N/A
- EPS
- GNRC 4.82
- ROIV 5.89
- Revenue
- GNRC $4,124,703,000.00
- ROIV $129,128,999.00
- Revenue This Year
- GNRC $9.21
- ROIV $15.98
- Revenue Next Year
- GNRC $8.29
- ROIV N/A
- P/E Ratio
- GNRC $33.32
- ROIV $1.86
- Revenue Growth
- GNRC 2.91
- ROIV 145.68
- 52 Week Low
- GNRC $108.89
- ROIV $9.69
- 52 Week High
- GNRC $195.94
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- GNRC 44.08
- ROIV 38.75
- Support Level
- GNRC $153.25
- ROIV $10.42
- Resistance Level
- GNRC $162.17
- ROIV $11.82
- Average True Range (ATR)
- GNRC 3.93
- ROIV 0.35
- MACD
- GNRC 1.06
- ROIV -0.11
- Stochastic Oscillator
- GNRC 76.61
- ROIV 29.21
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.